BioTeSys' colleagues regularly appears as speaker at public events and publish scientific articles. Information on those events and release notes, as well as company announcements can be found here at a glance.
An EU project to make the use of nanomaterials safer for everyone ...
A film about an ambitious project on aging named "MARK-AGE" ..
After back to back success, the Clinical Trials Innovation Programme is back this time in Frankfurt for its 9th edition on 26th-27th April 2018.
This year CTIP will include insights from the pharmaceutical professionals discussing hot industry topics, keynote speeches from experts in their fields and brainstorming sessions that will forge the formation of new partnerships and strengthen existing relationships. BioTeSys will attend CTIP and we are happy to discuss your questions!
Visit us this year at Vitafoods Europe 2018 in Geneva. We welcome you from 15th to 17th of May at the booth I55.
The French Ministry of Higher Education, Research and Innovation has once again approved BioTeSys GmbH as a research service provider under the research tax credit “CIR”. French customers of BioTeSys can claim a tax relief up to 30 % of the contract value of the R&D project for their research efforts.
The S.O.T. 57th Annual Meeting and ToxExpo is just around the corner and I wanted to invite you back to booth 1253 to learn what 3T and BioTeSys has been working on since our debut last year.
The gTOXXs system -which allows the AUREA in-vitro genotoxicity assay to be automated- has enjoyed distinguished success as many of the leading pharma companies and CRO's have approved the technology and are integrating it into their workflow. These emerging collaborations coincide with the development of new workflows to include skin and liver models with the development of even more cell lines on the horizon.
This year 3T and BioTeSys is also proud to display two posters: "Applicability of HepaRG cell line for automated assessment of DNA strand breaks." (D1529) and "Organotypic human epidermal skin models and genotoxicity - safety assessment for dermal applications." (D1523) showing the sensitivity, ease of use and robustness of the Aurea platform.
We are looking forward to meeting you in March and learning a great deal from you.